Sovereign Laboratories, LLC – FDA Warning Letter, Apr 7, 2020
On June 15, 2020, the FDA and FTC issued a Warning Letter to Prosov Labs and Sovereign Laboratories regarding their websites, www.prosovlabs.com and www.sovereignlaboratories.com. The FDA observed that the websites offered "PRO Vital C-LD®," "PRO Colostrum-LD®," "Vital C-LDTM," and "Colostrum-LD®" for sale, claiming to mitigate, prevent, treat, diagnose, or cure COVID-19.
The FDA determined these products are unapproved new drugs, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and are misbranded drugs under section 502 of the FD&C Act (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act (21 U.S.C. § 331(a) and (d)).
The letter cites the public health emergency and national emergency declarations related to COVID-19 as context for urgent FDA action. The company was requested to immediately cease selling these unapproved and unauthorized products for COVID-19 related claims. Examples of misleading claims from www.sovereignlaboratories.com were noted.
The
ID · fa631e11-6667-4d50-988b-96701ee5d9c6
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.